The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides.

2.50
Hdl Handle:
http://hdl.handle.net/10541/71040
Title:
The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides.
Authors:
Renehan, Andrew G; Frystyk, Jan; Howell, Anthony ( 0000-0002-3879-5991 ) ; O'Dwyer, Sarah T; Shalet, Stephen M; Flyvbjerg, Allan
Abstract:
BACKGROUND: Oral estrogen alone (EA) decreases concentrations of total IGF-I while increasing IGFBP-1, but data on other IGF-related peptides are inconsistent and/or sparse. Combined oral estrogen and progestin (EP) may have differential effects on IGF-related peptides dependent on its progestin-associated androgenic activity. The aim of this study was to clarify these relationships, as circulating IGF-related peptides are potential surrogates of predisposition to common chronic diseases. DESIGN: Using an open-labelled cross-sectional design within a bowel cancer screening trial (aged 55-64 years), we determined total IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in fasted serum from 210 healthy women and free IGF-I (by ultrafiltration), insulin, IGFBP-1 and IGFBP-1:IGF-I binary complex in a selected subset of 92 women. Unadjusted and adjusted (using generalized linear models) means were compared. RESULTS: Among EA users, mean concentrations for total IGF-I (adjusted P=0.004) and free IGF-I (P<0.001) were reduced, whereas mean concentrations of IGFBP-1 (P=0.001) and binary complex (P=0.01) were increased compared with non-users. Taken as a whole group, EP use was not associated with differences in concentrations of IGF-related peptides, but on sub-group analyses, mean concentrations associated with the use of progestins with reduced androgenic activity reflected the use of EA. By contrast, mean IGFBP-2 concentrations were significantly reduced among both EA (P=0.008) and EP (P=0.002) users, irrespective of androgenic activity. Neither EA nor EP influenced mean concentrations of IGF-II, insulin and IGFBP-3. CONCLUSIONS: The uses of oral sex steroid replacements are associated with significant changes in several IGF-related analytes in a preparation-specific manner, suggesting different regulatory mechanisms. However, the directions of these changes do not fit simple correlative models of predisposition to common diseases.
Affiliation:
Department of Surgery, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. arenehan@picr.man.ac.uk
Citation:
The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. 2007, 17 (3):210-9 Growth Horm. IGF Res.
Journal:
Growth Hormone & IGF Research
Issue Date:
Jun-2007
URI:
http://hdl.handle.net/10541/71040
DOI:
10.1016/j.ghir.2007.01.017
PubMed ID:
17360217
Type:
Article
Language:
en
ISSN:
1096-6374
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRenehan, Andrew G-
dc.contributor.authorFrystyk, Jan-
dc.contributor.authorHowell, Anthony-
dc.contributor.authorO'Dwyer, Sarah T-
dc.contributor.authorShalet, Stephen M-
dc.contributor.authorFlyvbjerg, Allan-
dc.date.accessioned2009-06-19T13:46:12Z-
dc.date.available2009-06-19T13:46:12Z-
dc.date.issued2007-06-
dc.identifier.citationThe effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. 2007, 17 (3):210-9 Growth Horm. IGF Res.en
dc.identifier.issn1096-6374-
dc.identifier.pmid17360217-
dc.identifier.doi10.1016/j.ghir.2007.01.017-
dc.identifier.urihttp://hdl.handle.net/10541/71040-
dc.description.abstractBACKGROUND: Oral estrogen alone (EA) decreases concentrations of total IGF-I while increasing IGFBP-1, but data on other IGF-related peptides are inconsistent and/or sparse. Combined oral estrogen and progestin (EP) may have differential effects on IGF-related peptides dependent on its progestin-associated androgenic activity. The aim of this study was to clarify these relationships, as circulating IGF-related peptides are potential surrogates of predisposition to common chronic diseases. DESIGN: Using an open-labelled cross-sectional design within a bowel cancer screening trial (aged 55-64 years), we determined total IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in fasted serum from 210 healthy women and free IGF-I (by ultrafiltration), insulin, IGFBP-1 and IGFBP-1:IGF-I binary complex in a selected subset of 92 women. Unadjusted and adjusted (using generalized linear models) means were compared. RESULTS: Among EA users, mean concentrations for total IGF-I (adjusted P=0.004) and free IGF-I (P<0.001) were reduced, whereas mean concentrations of IGFBP-1 (P=0.001) and binary complex (P=0.01) were increased compared with non-users. Taken as a whole group, EP use was not associated with differences in concentrations of IGF-related peptides, but on sub-group analyses, mean concentrations associated with the use of progestins with reduced androgenic activity reflected the use of EA. By contrast, mean IGFBP-2 concentrations were significantly reduced among both EA (P=0.008) and EP (P=0.002) users, irrespective of androgenic activity. Neither EA nor EP influenced mean concentrations of IGF-II, insulin and IGFBP-3. CONCLUSIONS: The uses of oral sex steroid replacements are associated with significant changes in several IGF-related analytes in a preparation-specific manner, suggesting different regulatory mechanisms. However, the directions of these changes do not fit simple correlative models of predisposition to common diseases.en
dc.language.isoenen
dc.subject.meshDisease-
dc.subject.meshDisease Susceptibility-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshEstrogen Replacement Therapy-
dc.subject.meshEstrogens-
dc.subject.meshFemale-
dc.subject.meshGonadal Steroid Hormones-
dc.subject.meshHormone Replacement Therapy-
dc.subject.meshHumans-
dc.subject.meshInsulin-Like Growth Factor Binding Proteins-
dc.subject.meshMiddle Aged-
dc.subject.meshPeptides-
dc.subject.meshProgestins-
dc.subject.meshSomatomedins-
dc.titleThe effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. arenehan@picr.man.ac.uken
dc.identifier.journalGrowth Hormone & IGF Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.